| | GAITHERSBURG, Md., March 6, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, today announced that it will participate in TD Cowen’s 43rd Annual Health Care Conference. | Conference Details: | | | | Fireside Chat | | | Date: | Wednesday, March 8, 2023 | | Time: | 9:50 – 10:20 a.m. Eastern Standard Time (EST) | | Location: | Boston Marriott Copley Place in Boston, Massachusetts | | Moderator: | Georgi Yordanov, Equity Research Analyst – Biotechnology | | Novavax participant: | John Trizzino, Chief Commercial Officer and Chief Business Officer | | | | | | Conference | | | Event: | Investor Meetings | | Date: | Wednesday, March 8, 2023 | | | | | | | | | | | | | Recordings
A replay of the recorded fireside session will be available through the Events & presentations page of the Company’s website at ir.novavax.com for 90 days from the date of the conference. About Novavax
Novavax, Inc. (Nasdaq: NVAX) promotes improved health by discovering, developing and commercializing innovative vaccines to protect against serious infectious diseases. Novavax, a global company based in Gaithersburg, Md., U.S., offers a differentiated vaccine platform that combines a recombinant protein approach, innovative nanoparticle technology and Novavax’s patented Matrix-M adjuvant to enhance the immune response. Focused on the world’s most urgent health challenges, Novavax is currently evaluating vaccines for COVID-19, influenza, and COVID-19 and influenza combined. Please visit novavax.com and LinkedIn for more information. CONTACTS Investors
Erika Schultz
240-268-2022
ir@novavax.com Media
Ali Chartan
240-720-7804
media@novavax.com  View original content to download multimedia:https://www.prnewswire.com/news-releases/novavax-to-participate-in-td-cowens-43rd-annual-health-care-conference-301762705.html
SOURCE Novavax, Inc. | |
